Stifel analyst David Grossman lowered the firm’s price target on Amwell (AMWL) to $5 from $6 and keeps a Hold rating on the shares. 2026 revenue guidance coming in about $40M below consensus reflects strategic portfolio restructuring, exiting lower-quality revenue streams, and client-specific contract adjustments, the analyst tells investors in a post-earnings note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell: Cost Controls and Margin Gains Offset by Weak Growth Outlook, Justifying a Hold Rating
- American Well: Strong Near-Term Performance but Limited Post-2026 Visibility Keeps Rating at Hold
- Amwell reports Q4 EPS ($1.52), consensus ($1.60)
- Amwell sees Q1 revenue $48M-53M, consensus $57.82M
- Amwell sees FY26 revenue $195M-$205M, consensus $240.41M